Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-11-2012 | Article

Antimicrobial properties of distinctin in an experimental model of MRSA-infected wounds

Authors: O. Simonetti, O. Cirioni, R. Ghiselli, G. Goteri, F. Orlando, L. Monfregola, S. De Luca, A. Zizzi, C. Silvestri, G. Veglia, A. Giacometti, M. Guerrieri, A. Offidani, A. Scaloni

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2012

Abstract

The aim of this study was to evaluate the efficacy of distinctin in the management of cutaneous methicillin-resistant Staphylococcus aureus (MRSA) wound infections in an experimental mouse model. Wounds, made in the panniculus carnosus of BALB/c mice, were inoculated with 5 × 10⁷ colony-forming units (CFU) of MRSA. Mice were treated with topical distinctin (1 mg/kg of body weight), topical teicoplanin (7 mg/kg of body weight), intraperitoneal teicoplanin (7 mg/kg of body weight); topical teicoplanin and daily intraperitoneal teicoplanin; topical distinctin and daily intraperitoneal teicoplanin. Bacterial cultures of excised tissues and histological examination of microvessel density and of vascular endothelial growth factor (VEGF) expression were studied. It was found that topical distinctin combined with parenteral teicoplanin inhibited bacterial growth to levels comparable with those observed in uninfected animals. Wounded areas of animals treated with distinctin were characterized by a more mature granulation tissue, with a more organized and denser type of connective tissue, compared to mice treated only with teicoplanin. Treatment with topical distinctin had a significant impact on VEGF expression and microvessel density. The combined use of distinctin with teicoplanin may be useful in the management of infected wounds by significantly inhibiting bacterial growth and accelerating the repair process.

Available only for authorised users

Saleh K, Sonesson A, Persson B, Riesbeck K, Schmidtchen A (2011) A descriptive study of bacterial load of full-thickness surgical wounds in dermatologic surgery. Dermatol Surg 37(7):1014–1022PubMedCrossRef

Lowy FD (2003) Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 111:1265–1273PubMed

Bone RC (1994) Gram-positive organisms and sepsis. Arch Intern Med 154:26–34PubMedCrossRef

Howell-Jones RS, Wilson MJ, Hill KE, Howard AJ, Price PE, Thomas DW (2005) A review of the microbiology, antibiotic usage and resistance in chronic skin wounds. J Antimicrob Chemother 55:143–149PubMedCrossRef

Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339:520–532PubMedCrossRef

Hancock RE, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24(12):1551–1557PubMedCrossRef

Pukala TL, Bowie JH, Maselli VM, Musgrave IF, Tyler MJ (2006) Host-defence peptides from the glandular secretions of amphibians: structure and activity. Nat Prod Rep 23(3):368–393PubMedCrossRef

Rinaldi AC (2002) Antimicrobial peptides from amphibian skin: an expanding scenario. Curr Opin Chem Biol 6(6):799–804PubMedCrossRef

Lipsky BA, Holroyd KJ, Zasloff M (2008) Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis 47:1537–1545PubMedCrossRef

10.

Batista CV, Scaloni A, Rigden DJ, Silva LR, Rodrigues Romero A, Dukor R, Sebben A, Talamo F, Bloch C (2001) A novel heterodimeric antimicrobial peptide from the tree-frog Phyllomedusa distincta. FEBS Lett 494(1–2):85–89PubMedCrossRef

11.

Cirioni O, Ghiselli R, Orlando F, Silvestri C, De Luca S, Salzano AM, Mocchegiani F, Saba V, Scalise G, Scaloni A, Giacometti A (2008) Efficacy of the amphibian peptide distinctin in a neutropenic mouse model of staphylococcal sepsis. Crit Care Med 36(9):2629–2633PubMedCrossRef

12.

Dalla Serra M, Cirioni O, Vitale RM, Renzone G, Coraiola M, Giacometti A, Potrich C, Baroni E, Guella G, Sanseverino M, De Luca S, Scalise G, Amodeo P, Scaloni A (2008) Structural features of distinctin affecting peptide biological and biochemical properties. Biochemistry 47(30):7888–7899PubMedCrossRef

13.

Lee IH, Lee YS, Kim CH, Kim CR, Hong T, Menzel L, Boo LM, Pohl J, Sherman MA, Waring A, Lehrer RI (2001) Dicynthaurin: an antimicrobial peptide from hemocytes of the solitary tunicate, Halocynthia aurantium. Biochim Biophys Acta 1527:141–148PubMedCrossRef

14.

Jang WS, Kim KN, Lee YS, Nam MH, Lee IH (2002) Halocidin: a new antimicrobial peptide from hemocytes of the solitary tunicate, Halocynthia aurantium. FEBS Lett 521:81–86PubMedCrossRef

15.

Yomogida S, Nagaoka I, Yamashita T (1996) Purification of the 11- and 5-kDa antibacterial polypeptides from guinea pig neutrophils. Arch Biochem Biophys 328:219–226PubMedCrossRef

16.

Scocchi M, Zelezetsky I, Benincasa M, Gennaro R, Mazzoli A, Tossi A (2005) Structural aspects and biological properties of the cathelicidin PMAP-36. FEBS J 272:4398–4406PubMedCrossRef

17.

Raimondo D, Andreotti G, Saint N, Amodeo P, Renzone G, Sanseverino M, Zocchi I, Molle G, Motta A, Scaloni A (2005) A folding-dependent mechanism of antimicrobial peptide resistance to degradation unveiled by solution structure of distinctin. Proc Natl Acad Sci USA 102(18):6309–6314PubMedCrossRef

18.

Jang WS, Kim CH, Kim KN, Park SY, Lee JH, Son SM, Lee IH (2003) Biological activities of synthetic analogs of halocidin, an antimicrobial peptide from the tunicate Halocynthia aurantium. Antimicrob Agents Chemother 47:2481–2486PubMedCrossRef

19.

Okuda D, Yomogida S, Tamura H, Nagaoka I (2006) Determination of the antibacterial and lipopolysaccharide-neutralizing regions of guinea pig neutrophil cathelicidin peptide CAP11. Antimicrob Agents Chemother 50:2602–2607PubMedCrossRef

20.

Jang WS, Lee SC, Lee YS, Shin YP, Shin KH, Sung BH, Kim BS, Lee SH, Lee IH (2007) Antimicrobial effect of halocidin-derived peptide in a mouse model of Listeria infection. Antimicrob Agents Chemother 51(11):4148–4156PubMedCrossRef

21.

Shin YP, Park HJ, Shin SH, Lee YS, Park S, Jo S, Lee YH, Lee IH (2010) Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases. Antimicrob Agents Chemother 54(7):2855–2866PubMedCrossRef

22.

Lauer G, Sollberg S, Cole M, Flamme I, Stürzebecher J, Mann K, Krieg T, Eming SA (2000) Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Invest Dermatol 115:12–18PubMedCrossRef

23.

Byrne AM, Bouchier-Hayes DJ, Harmey JH (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9:777–794PubMedCrossRef

24.

Cianfarani F, Tommasi R, Failla CM, Viviano MT, Annessi G, Papi M, Zambruno G, Odorisio T (2006) Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endothelial growth factor transcription in the ulcer bed. Br J Dermatol 154:34–41PubMedCrossRef

25.

Frantz S, Vincent KA, Feron O, Kelly RA (2005) Innate immunity and angiogenesis. Circ Res 96:15–26PubMedCrossRef

26.

Asai J, Takenaka H, Katoh N, Kishimoto S (2006) Dibutyryl cAMP influences endothelial progenitor cell recruitment during wound neovascularization. J Invest Dermatol 126:1159–1167PubMedCrossRef

27.

Shinzawa H, Takeda A, Sone Y, Murashita K, Uchinuma E (2007) Wound healing process of a full-thickness skin wound model in rats. Int Surg 92:63–72PubMed

28.

Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K, Hashimoto K, Nagaoka I, Okumura K, Ogawa H (2007) Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 127:594–604PubMedCrossRef

29.

Pace JL, Yang G (2006) Glycopeptides: update on an old successful antibiotic class. Biochem Pharmacol 71:968–980PubMedCrossRef

30.

Clinical and Laboratory Standards Institute (CLSI) (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard M7-A6. CLSI, Villanova, PA

31.

Eliopoulos GM, Moellering RC Jr (1996) Antimicrobial combinations. In: Lorian V (ed) Antibiotics in laboratory medicine, 4th edn. Williams & Wilkins, Baltimore, pp 330–393

32.

Simonetti O, Cirioni O, Goteri G, Ghiselli R, Kamysz W, Kamysz E, Silvestri C, Orlando F, Barucca C, Scalise A, Saba V, Scalise G, Giacometti A, Offidani A (2008) Temporin A is effective in MRSA-infected wounds through bactericidal activity and acceleration of wound repair in a murine model. Peptides 29(4):520–528PubMedCrossRef

33.

Fung HB, Chang JY, Kuczynski SA (2003) Practical guide to the treatment of complicated skin and soft tissue infections. Drugs 63:1459–1480PubMedCrossRef

34.

Bergmann S, Hammerschmidt S (2007) Fibrinolysis and host response in bacterial infections. Thromb Haemost 98(3):512–520PubMed

35.

[No authors listed] (1993) Proteolytic enzymes in coagulation, fibrinolysis, and complement activation. Part A. Mammalian blood coagulation factors and inhibitors. Methods Enzymol 222:1–559CrossRef

36.

Yeaman MR, Yount NY (2003) Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 55(1):27–55PubMedCrossRef

37.

Vaara M, Porro M (1996) Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrob Agents Chemother 40:1801–1805PubMed

38.

Mangoni ML, Rinaldi AC, Di Giulio A, Mignogna G, Bozzi A, Barra D, Simmaco M (2000) Structure–function relationships of temporins, small antimicrobial peptides from amphibian skin. Eur J Biochem 267:1447–1454PubMedCrossRef

39.

Rinaldi AC, Mangoni ML, Rufo A, Luzi C, Barra D, Zhao H, Kinnunen PK, Bozzi A, Di Giulio A, Simmaco M (2002) Temporin L: antimicrobial, haemolytic and cytotoxic activities, and effects on membrane permeabilization in lipid vesicles. Biochem J 368:91–100PubMedCrossRef

40.

Resende JM, Moraes CM, Munhoz VH, Aisenbrey C, Verly RM, Bertani P, Cesar A, Piló-Veloso D, Bechinger B (2009) Membrane structure and conformational changes of the antibiotic heterodimeric peptide distinctin by solid-state NMR spectroscopy. Proc Natl Acad Sci U S A 106(39):16639–16644PubMedCrossRef

41.

Martin P (1997) Wound healing—aiming for perfect skin regeneration. Science 276:75–81PubMedCrossRef

42.

Santoro MM, Gaudino G (2005) Cellular and molecular facets of keratinocyte reepithelization during wound healing. Exp Cell Res 304:274–286PubMedCrossRef

43.

Werner S, Krieg T, Smola H (2007) Keratinocyte–fibroblast interactions in wound healing. J Invest Dermatol 127:998–1008PubMedCrossRef

44.

Naldini A, Carraro F (2005) Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy 4:3–8PubMedCrossRef

45.

Ho QT, Kuo CJ (2007) Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 39(7–8):1349–1357PubMedCrossRef

Title: Antimicrobial properties of distinctin in an experimental model of MRSA-infected wounds
Authors: O. Simonetti
O. Cirioni
R. Ghiselli
G. Goteri
F. Orlando
L. Monfregola
S. De Luca
A. Zizzi
C. Silvestri
G. Veglia
A. Giacometti
M. Guerrieri
A. Offidani
A. Scaloni
Publication date: 01-11-2012
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2012
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-012-1663-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2012

Volatile organic compound analysis by ion molecule reaction mass spectrometry for Gram-positive bacteria differentiation

Utility and safety of procalcitonin in an antimicrobial stewardship program (ASP) in patients with malignancies

Toothbrushing does not need to reduce the risk of VAP to be indispensable

Effectiveness of vaginal tablets containing lactobacilli versus pH tablets on vaginal health and inflammatory cytokines: a randomized, double-blind study

MALDI-TOF mass spectrometry and microsatellite markers to evaluate Candida parapsilosis transmission in neonatal intensive care units

Infective endocarditis in intravenous drug abusers: an update

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials